The Effects of One Month of Therapy with the Long-acting Bronchodilator Tiotropium on Ventilation Heterogeneity in Patients with Chronic Obstructive Pulmonary Disease

Woolcock Institute of Medical Research0 sites45 target enrollmentJanuary 29, 2015

Overview

No summary available.

Registry

who.int

Start Date

January 29, 2015

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

•Adults with physician\-diagnosed mild\-moderate chronic obstructive pulmonary disease, with history of current or past smoking (total exposure \> 10 pack years)

•\* Use of tiotropium or any other LAMA or LABA within the previous 4 weeks
•\* Musculoskeletal (for example, severe arthritis) or other conditions which limit the ability to walk at near\-maximal pace
•\* Significant cardiac disease (ischaemic heart disease or arrhythmia) deemed by the investigators or the subject’s treating cardiologist to make it unsafe for the subject to undertake a supervised near\-maximal exercise test
•\* Documented hypersensitivity to, or intolerance of, anti\-cholinergic therapies
•\* Significant respiratory infection or documented exacerbation of COPD within the previous 6 weeks
•\* Other active or chronic respiratory pathologies (for example, interstitial lung disease, asthma, chest wall pathology causing ventilatory restriction)
•\* Past history of lung surgery (including lobectomy or pneumonectomy, but not lung biopsy) or thoracic radiation therapy (excluding isolated mediastinal radiation therapy with no evidence of subsequent pulmonary fibrosis)
•\* Any major comorbidities deemed to impact on respiratory physiology or symptoms, including severe on uncontrolled heart failure, morbid obesity, muscular or neurological disorders causing respiratory muscle weakness or dysfunctional swallowing
•\* History of chronic kidney disease (moderate to severe, eGFR less than or equal to 45 mL/min/1\.73m2\) or severe hepatic impairment
•\* Unable to perform lung function testing at the enrollment visit